Publicaciones en las que colabora con Valentí Fuster (60)

2024

  1. Apolipoprotein E-ϵ2 and Resistance to Atherosclerosis in Midlife: The PESA Observational Study

    Circulation Research, Vol. 134, Núm. 4, pp. 411-424

2023

  1. Cardiac Insulin Resistance in Subjects With Metabolic Syndrome Traits and Early Subclinical Atherosclerosis

    Diabetes Care, Vol. 46, Núm. 11, pp. 2050-2057

  2. Determinants of Progression and Regression of Subclinical Atherosclerosis Over 6 Years

    Journal of the American College of Cardiology, Vol. 82, Núm. 22, pp. 2069-2083

  3. Early insulin resistance in normoglycemic low-risk individuals is associated with subclinical atherosclerosis

    Cardiovascular Diabetology, Vol. 22, Núm. 1

  4. Longitudinal interplay between subclinical atherosclerosis, cardiovascular risk factors, and cerebral glucose metabolism in midlife: results from the PESA prospective cohort study

    The Lancet Healthy Longevity, Vol. 4, Núm. 9, pp. e487-e498

  5. Subclinical atherosclerosis and accelerated epigenetic age mediated by inflammation: a multi-omics study

    European heart journal, Vol. 44, Núm. 29, pp. 2698-2709

2022

  1. Bone marrow activation in response to metabolic syndrome and early atherosclerosis

    European Heart Journal, Vol. 43, Núm. 19, pp. 1809-1828

  2. Effects of a comprehensive lifestyle intervention on cardiovascular health: the TANSNIP-PESA trial

    European heart journal, Vol. 43, Núm. 38, pp. 3732-3745

  3. New 3-Dimensional Volumetric Ultrasound Method for Accurate Quantification of Atherosclerotic Plaque Volume

    JACC: Cardiovascular Imaging, Vol. 15, Núm. 6, pp. 1124-1135

  4. Polypill Strategy in Secondary Cardiovascular Prevention

    The New England journal of medicine, Vol. 387, Núm. 11, pp. 967-977

  5. Unbiased plasma proteomics discovery of biomarkers for improved detection of subclinical atherosclerosis

    eBioMedicine, Vol. 76

2021

  1. Glycated Hemoglobin and Subclinical Atherosclerosis in People Without Diabetes

    Journal of the American College of Cardiology, Vol. 77, Núm. 22, pp. 2777-2791

  2. Progression of Early Subclinical Atherosclerosis (PESA) Study: JACC Focus Seminar 7/8

    Journal of the American College of Cardiology, Vol. 78, Núm. 2, pp. 156-179

  3. Subclinical Atherosclerosis and Brain Metabolism in Middle-Aged Individuals: The PESA Study

    Journal of the American College of Cardiology, Vol. 77, Núm. 7, pp. 888-898

  4. Triglycerides and Residual Atherosclerotic Risk

    Journal of the American College of Cardiology, Vol. 77, Núm. 24, pp. 3031-3041

2020

  1. Association Between Body Size Phenotypes and Subclinical Atherosclerosis

    The Journal of clinical endocrinology and metabolism, Vol. 105, Núm. 12

  2. Association Between Left Ventricular Noncompaction and Vigorous Physical Activity

    Journal of the American College of Cardiology, Vol. 76, Núm. 15, pp. 1723-1733

  3. Complement C5 Protein as a Marker of Subclinical Atherosclerosis

    Journal of the American College of Cardiology, Vol. 75, Núm. 16, pp. 1926-1941

  4. Lipidomic profiling identifies signatures of metabolic risk

    EBioMedicine, Vol. 51

  5. Machine Learning Improves Cardiovascular Risk Definition for Young, Asymptomatic Individuals

    Journal of the American College of Cardiology, Vol. 76, Núm. 14, pp. 1674-1685